Published on GHDx (https://ghdx.healthdata.org.)

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

General Info

Geography 
Argentina (ARG)
Australia (AUS)
Austria (AUT)
Belgium (BEL)
Brazil (BRA)
Canada (CAN)
China (CHN)
Hong Kong
Denmark (DNK)
Finland (FIN)
France (FRA)
Germany (DEU)
Hungary (HUN)
Israel (ISR)
Italy (ITA)
Malaysia (MYS)
Mexico (MEX)
Netherlands (NLD)
New Zealand (NZL)
Poland (POL)
Portugal (PRT)
Singapore (SGP)
Sweden (SWE)
Taiwan (Province of China) (TWN)
Trinidad and Tobago (TTO)
Port of Spain
United Kingdom (GBR)
United States of America (USA)
Puerto Rico
View all
Time period covered 
January, 1996 - December, 2000
Data type
Scientific literature
Keywords 
Cardiovascular and circulatory diseases

Citation

Authors 
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group
Journal 
N Engl J Med
Pages 
851-60
Publication year 
2001
Suggested citation 
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12): 851-60.
Source URL:https://ghdx.healthdata.org./record/renoprotective-effect-angiotensin-receptor-antagonist-irbesartan-patients-nephropathy-due